Bregal Sagemount Makes Strategic Growth Investment in LSPedia

Bregal Sagemount, a growth-focused private equity firm, has made a strategic growth investment in LSPedia, a provider of mission-critical compliance, traceability, and supply chain software for the pharmaceutical industry. The announcement was made on May 26, 2026, marking a significant step in LSPedia’s expansion and product development plans.

While the financial terms of the investment have not been disclosed, the partnership is designed to accelerate LSPedia’s innovation pipeline, customer base expansion, and global growth strategy. The deal involves Bregal Sagemount’s Basecamp fund leading the investment, with legal advisory support from Koley Jessen P.C., L.L.O. for LSPedia and Goodwin Procter LLP for Bregal Sagemount.

Founded in 2013 by Riya Cao, LSPedia specializes in software solutions that help pharmaceutical manufacturers, wholesale distributors, dispensers, healthcare systems, and government agencies manage serialized product movement and verification. Its cloud-based platform supports compliance with global regulations such as the Drug Supply Chain Security Act (DSCSA) and the Falsified Medicines Directive (FMD), covering over 40 countries.

Currently, LSPedia serves more than 1,600 customers and processes over 900 million serialized units annually through a network of more than 750,000 trading partner connections. This scale positions the company as a critical data and workflow layer in pharmaceutical supply chains, supporting both regulatory compliance and operational efficiency.

Riya Cao, Founder and CEO of LSPedia, stated, “We built LSPedia from the ground up, bootstrapped with a focus on the operational realities of pharmaceutical compliance. Together with Sagemount, we see a significant opportunity to continue expanding the platform, deepening customer relationships, and investing in the next generation of supply chain connectivity and intelligence. With innovations like OneScan and Traceability AI, we’re helping customers achieve supply chain visibility, integration, and predictive insights with the speed and scale today’s environment demands.”

LSPedia’s flagship product, OneScan, offers a scan-once workflow that captures serialized product events at the point of handling and routes data automatically to the appropriate workflows. This reduces operational friction and enhances real-time supply chain visibility. The company also leverages AI-driven intelligence to provide actionable insights beyond compliance, supporting decision-making across supply chain operations.

Zuhair Khan, Partner and Co-Head of Basecamp at Bregal Sagemount, commented, “LSPedia has built a uniquely comprehensive platform that serves participants across the entire pharmaceutical supply chain. The Company’s focus on helping customers meet regulatory requirements while also providing operational value creates a compelling foundation for long-term growth. We are excited to partner with Riya and the team as they accelerate innovation, including advanced traceability and analytics, to support customers worldwide.”

The investment aligns with broader industry trends emphasizing supply chain transparency, regulatory compliance, and the integration of advanced analytics and AI technologies. As pharmaceutical supply chains grow more complex, solutions like LSPedia’s are increasingly critical for managing serialized product data and ensuring compliance across multiple jurisdictions.

Financial details such as valuation and deal multiples have not been disclosed. The investment is expected to fund product enhancements, including expanded data coverage, improved platform scalability, and new client-facing tools. Bregal Sagemount’s operational expertise will support LSPedia in scaling its platform and expanding into adjacent markets.

Looking ahead, the partnership will focus on integrating advanced analytics capabilities and expanding LSPedia’s geographic footprint, potentially into Europe and Asia. The companies will also address integration challenges such as aligning technology platforms, retaining key talent, and managing cultural integration.

This strategic growth investment positions LSPedia to strengthen its market share in pharmaceutical compliance software and accelerate innovation in supply chain traceability and intelligence.